Article

Product Preview

Products and services in the pipeline from Nymox Pharmaceuticals Corp.; OncoGenex Pharmaceuticals, Inc.; Ampio Pharmaceuticals, Inc.; Aragon Pharmaceuticals; Sophiris Bio Inc.; Genomic Health, Inc.; OxThera AB; Aeterna Zentaris Inc.; and Tengion, Inc.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Joseph Song, MD, on the emergence of new suction-based devices for stone disease
Joseph Song, MD, on the emergence of new suction-based devices for stone disease
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES, answers a question during a Zoom video intervew
How eating disorders affect bladder and pelvic floor health
2 experts in this video
Fitting Oral ADT Options Into the Prostate Cancer Treatment Plans
2 experts in this video
The Current Landscape of ADT in Prostate Cancer
Daniel D. Joyce, MD, MS, answers a question during a Zoom video interview
Daniel D. Joyce, MD, MS, discusses the economics of trimodal therapy in MIBC
Sarah Razavi, MD, answers a question during a Zoom video interview
Sarah Razavi, MD, outlines strategies for mitigate surgeon discomfort during URS
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
Can ctDNA detect molecular residual disease in NMIBC?
Kevin T. McVary, MD, FACS, answers a question during a Zoom video interview
Expert discusses setting realistic expectations for Rezum for BPH
1 expert is featured in this series.
Considering Therapy De-Intensification: Balancing Adverse Effects and PSA Response
Nicolette G. Payne, MD, answers a question during a Zoom video interview
Nicolette G. Payne, MD, discusses risk factors for burnout among pediatric urologists
Related Content
Aquablation procedures for prostate cancer completed at ambulatory surgery center
July 24th 2025

Aquablation procedures for prostate cancer completed at ambulatory surgery center

Hannah Clarke
The WATER IV PCa trial is comparing first-line Aquablation therapy with radical prostatectomy for the treatment of patients with localized prostate cancer.
Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD
July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD
Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.
FDA clears image-guided navigation platform for focal therapy in prostate cancer
July 23rd 2025

FDA clears image-guided navigation platform for focal therapy in prostate cancer

Hannah Clarke
The new advanced annotation workflow on the UroNav System is designed to work in tandem with DynaCAD Urology to support focal therapy planning.
Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD
June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD
Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.
When to report 50320 with 49187 for nephrectomy procedures
July 23rd 2025

When to report 50320 with 49187 for nephrectomy procedures

Jonathan Rubenstein, MD Mark Painter
"As always, we encourage you to communicate among all team members and pay attention to your documentation," write Jonathan Rubenstein, MD, and Mark Painter.
Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation
Published: July 22nd 2025 | Updated: July 23rd 2025

Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation

Hannah Clarke
The PRESERVE trial met its primary end point by demonstrating a negative in-field biopsy rate of 71% at 12 months.
© 2025 MJH Life Sciences

All rights reserved.